Wikidata

(Q63571887)

English

A Global Study of the Efficacy and Safety of Midostaurin + Chemotherapy in Newly Diagnosed Patients With FLT3 Mutation Negative (FLT3-MN) Acute Myeloid Leukemia (AML)

clinical trial

In more languages

Statements

title
A Phase III, Randomized, Double-blind Study of Chemotherapy With Daunorubicin or Idarubicin and Cytarabine for Induction and Intermediate Dose Cytarabine for Consolidation Plus Midostaurin (PKC412) or Chemotherapy Plus Placebo in Newly Diagnosed Patients With FLT-3 Mutation Negative Acute Myeloid Leukemia (AML) (English)
0 references
sponsor
Novartis
0 references
country
Argentina
0 references
Australia
0 references
Austria
0 references
Belgium
0 references
Brazil
0 references
Bulgaria
0 references
France
0 references
Germany
0 references
Israel
0 references
Italy
0 references
Japan
0 references
Norway
0 references
Poland
0 references
Portugal
0 references
Spain
0 references
Switzerland
0 references
Taiwan
0 references
Turkey
0 references
main subject
midostaurin
0 references
start time
7 January 2018
0 references
end time
15 October 2019
0 references
number of participants
502
0 references
research intervention
cytarabine
0 references
daunorubicin
0 references
idarubicin
0 references
midostaurin
0 references
staurosporine
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q63571887&oldid=1857254547"